A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.

Sant P. Chawla,Brian A. Van Tine,Seth M. Pollack,Kristen N. Ganjoo,Anthony D. Elias,Richard F. Riedel,Steven Attia,Edwin Choy,Scott H. Okuno,Mark Agulnik,Margaret von Mehren,Michael B. Livingston,Vicki L. Keedy,Claire F. Verschraegen,Tony Philip,Gerry C. Bohac,Sergey Yurasov,Hailing Lu,Michael Chen,Robert G. Maki

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.

2019

11011Background: CMB305 (C) is an immunotherapy designed to generate an anti-NY-ESO-1 immune response (IR). C consists of a dendritic cell-targeting lentiviral vector encoding NY-ESO-1 gene (LV305)...

Keywords:

Pathology
Immune system
Immunotherapy
Soft tissue sarcoma
Randomized controlled trial
NY-ESO-1
Viral vector
Cancer research
Immunogenicity
Medicine
Atezolizumab
Sarcoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations